Compare Devon Energy Corp (DVN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Viatris Inc — how do they compare? Devon Energy Corp trades at $42.93 (market cap $49.52B), while Viatris Inc trades at $16.6 (market cap $19.44B). The key difference: Devon Energy Corp is far larger — about 2.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| DVN | VTRS | |
|---|---|---|
Market Cap | $49.52B | $19.44B |
Sector | Energy | Health |
52-Week High | $52.07 | $17.39 |
52-Week Low | $31.74 | $8.74 |
Enterprise Value | $56.29B | $31.65B |
Dividend Yield | 2.42% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $43.35, down 0.12% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 11.96, net income margin of 13.71%, and consistent cash flow generation. Recent news highlights activist pressure for asset sales and the integration benefits from the Coterra acquisition, targeting $2 billion in synergies by 2027.
DVN presents a compelling value opportunity with analyst consensus bullish (71% buy ratings) and a price target of $60.18, implying 39% upside. Risks include volatile energy prices, execution of merger synergies, and activist investor demands. Earnings growth and free cash flow remain key catalysts for shareholder returns.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
